![]() ![]() The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.Įxclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. ![]() The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.Ī drug patent is assigned by the U.S. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention relates to therapeutic combinations of -phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2 hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations. The present invention relates to therapeutic combinations of -phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The present invention relates to therapeutic combinations of -phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one(emtricitabine, Emtriva™, (-)-cis FTC) and their physiologically functional derivatives. Compositions and methods for combination antiviral therapy.Patent and Trademark Office at any time during a drug's development and may include a wide range of claims. Ask your health care provider for advice if you are unsure about the online purchase of any medication. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. ![]() These medications may be counterfeit and potentially unsafe. Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Truvada. The following products are equivalent to Truvada and have been approved by the FDA: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (emtricitabine tenofovir disoproxil fumarate tablet oral)ĮMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (emtricitabine tenofovir disoproxil fumarate tablet oral) However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. Has a generic version of Truvada been approved?Ī generic version of Truvada has been approved by the FDA. Truvada is a brand name of emtricitabine/tenofovir, approved by the FDA in the following formulation(s): TRUVADA (emtricitabine tenofovir disoproxil fumarate - tablet oral) ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |